

## Advances Toward a Cure for HIV

**Janet M. Siliciano, PhD**  
Associate Professor of Medicine  
Johns Hopkins University  
Baltimore, Maryland

---

---

---

---

---

---

---

### Financial Relationships With Commercial Entities

Dr Siliciano has served on the scientific advisory board for Gilead Sciences, Inc. Her lab has received a grant from Gilead Sciences, Inc. (Updated 08/3/20)

Slide 2 of 50

---

---

---

---

---

---

---

### Learning Objectives

After attending this presentation, learners will be able to:

- Describe basic mechanisms that allow HIV to persist despite antiretroviral therapy (ART)
- Recognize how proliferation of latently infected resting CD4+ T cells contributes to viral persistence
- Describe 1 current approach for achieving an HIV cure

Slide 3 of 50

---

---

---


---

---

---

---

## Magnitude of the problem



38,000,000 infected

23,000,000 on ART

3 people cured

Slide 4 of 50

---

---

---

---


---

---

---

---

## HIV replication dynamics



Wong et al. Nature 1995  
Ho et al. Nature 1995  
Perron et al. Nature 1997  
Finzi et al. Nature Med 1999  
Domenici et al. JAMA 1999  
Dionisi et al. PNAS 2005  
Bull and Rasmussen, 2010

Slide 5 of 50

---

---

---

---


---

---

---

---

## Physiology of resting and activated CD4<sup>+</sup> T cells



Slide 6 of 50

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---

## Establishment and maintenance of a latent reservoir



Slide 10 of 50

---

---

---

---


---

---

---

---

## HIV gene expression depends on inducible host factors



Nabel and Baltimore, *Nature* 1987  
 Tong-Starksen et al, *PNAS* 1987  
 Duh et al, *PNAS* 1989  
 Konishi et al, *Immunity* 1997

Slide 11 of 50

---

---

---

---


---

---

---

---

## A stable latent reservoir for HIV



Slide 12 of 50

---

---

---

---


---

---

---

---

## Reactivation of latent HIV



Slide 13 of 50

---

---

---

---


---

---

---

---

## Quantitative viral outgrowth assay



Slide 14 of 50

Chun et al. *Nature Med* 1995  
Chun et al. *Nature* 1997  
Finzi et al. *Science* 1997

---

---

---

---


---

---

---

---

## Slow decay of latently infected CD4+ T cells



Slide 15 of 50

Finzi et al. *Nature Med.*, 1999  
Siliciano et al. *Nature Med.*, 2003

---

---

---


---

---

---

---

---



Slide 16 of 50

---

---

---


---

---

---

---

---



Slide 17 of 50

---

---

---


---

---

---

---

---



Slide 18 of 50

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---

## Intact proviruses decay more rapidly than defective proviruses




- Cells with intact proviruses decay more rapidly than cells with defective proviruses
- This may indicate some immune pressure on infected cells during ART.
- This decay is slow! In first 7 years,  $t_{1/2}$  is close to 44 months. Subsequently, even slower

Slide 22 of 50


Peluso et al. JCI Insight 2020

## Response of resting T cells to antigen



Slide 23 of 50


## Infected cells can also proliferate



Slide 24 of 50



### The latent reservoir



Slide 28 of 50

---

---

---


---

---

---

---

### Clones of latently infected cells



Slide 29 of 50

---

---

---


---

---

---

---

### Clones of latently infected cells



Slide 30 of 50

---

---

---


---

---

---

---

### Infected cells can also proliferate



Slide 31 of 50

---

---

---

---


---

---

---

---

### Slow decay of the latent reservoir in resting CD4<sup>+</sup> T cells



Slide 32 of 50

Finzi et al. *Nature Med* 1999  
J. Siliciano et al. *Nature Med* 2003

---

---

---

---


---

---

---

---

### Clones of latently infected cells wax and wane



Slide 33 of 50

---

---

---

---


---

---

---

---

**Clones of latently infected cells  
wax and wane**



Slide 34 of 50

---

---

---


---

---

---

---

**Clones of latently infected cells  
wax and wane**



Slide 35 of 50

---

---

---


---

---

---

---

**Clones of latently infected cells  
wax and wane**



Slide 36 of 50

---

---

---


---

---

---

---

**Clones of latently infected cells  
wax and wane**



Slide 37 of 50

---

---

---


---

---

---

---

**Clones of latently infected cells  
wax and wane**



Slide 38 of 50

---

---

---


---

---

---

---

**Clones of latently infected cells  
wax and wane**



Slide 39 of 50

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---


## Assessing LRA efficacy



Slide 43 of 50

- Might cause blips
- Should reduce reservoir as determined by QVOA or IPDA
- Should delay rebound on interruption of ART


## Clinical trial of romidepsin



Slide 44 of 50

Courtesy of O. Segaud, Aarhus University

## Broadly neutralizing antibodies




Slide 45 of 50

- Neutralize diverse HIV isolates
- Arise slowly, generally after virus has already escaped
- Can be administered passively as infusion or with AAV vectors
- Block infection and target infected cells for killing


Borsignoni et al. Imm Rev 2017

## Effects of antibodies



Slide 46 of 50

## Clinical trials of bNABs




- bNAb VRC01 infused just prior to and during analytical treatment interruption (ATI)

Slide 47 of 50

Bar et al NEJM 2016  
Sabin et al JCI 2015

## Clinical trials of bNABs



Slide 48 of 50

Bar et al NEJM 2016  
Sabin et al JCI 2015

## Conclusions

- The latent reservoir in resting CD4+ T cells is the major barrier to cure
- Accurate measurement of the reservoir is important for evaluating cure interventions and requires distinguishing intact proviruses from defective ones. This can be done with a novel assay, the IPDA.
- The reservoir is maintained by the proliferation of infected cells in response to antigens. This is a serious problem for cure efforts.
- Eliminating the reservoir through the "shock and kill" strategy will require finding better ways to turn on latent HIV and better ways to induce the killing of productively infected cells
- Broadly neutralizing antibodies are of great interest in the HIV vaccine field and may also be useful to enhance killing of infected cells.

Slide 49 of 50

---

---

---

---

---

---

---

## Thank you

### Collaborators

Steve Deeks  
Rebecca Hoh  
Greg Laird  
Katie Bar  
Pablo Tebas

### Funding

Gilead (unrestricted research grant)  
Howard Hughes Medical Institute  
NIH: Martin Delaney Collaboratories  
Bill and Melinda Gates Foundation



Martin Delaney  
Collaboratories



Howard Hughes  
Medical Institute

Slide 50 of 50

---

---

---

---

---

---

---

**2020** Ryan White  
HIV/AIDS Program  
CLINICAL CONFERENCE

## Question-and-Answer Session

---

---

---

---

---

---

---